세계의 콜라겐 및 히알루론산 관절내 주사 시장 : 제품 유형, 용도, 유통경로, 지역별(-2035년)

Global Collagen and Hyaluronic Acid Intra-Articular Injections Market by Product Type [Hyaluronic Acid Injection (Single Injection, Multiple Injection), Collagen Injection, Combination of Hyaluronic Acid and Collagen], by Application (Knee Osteoarthritis, Joint Pains, Veterinary Applications, Post-Operative Recovery, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global collagen and hyaluronic acid intra-articular injections market is projected to expand at a 6.15% CAGR, reaching an estimated value of USD 6,324.80 million by 2035. Hyaluronic acid and collagen are injected directly into joints to treat joint disorders. While hyaluronic acid is expected to be the perfect lubricant and shock absorber, collagen, formed of the most basic unit of cartilage, supports the cartilage structure and regeneration. To reduce the stiffness and pain, the patients get back their lost functions and mobility, and this becomes a great step towards the final idea of surgery discontinuance.

Manufacturers are seeking to supply the demand that comes from the high rate of Osteoarthritis, Rheumatoid Arthritis, and sports injuries affecting the joint, and collagen and hyaluronic acid are becoming more and more popular as the solution. Due to the aging of the population and proliferating risk factors like obesity and inactivity, patients tend to decide in favor of non-surgical therapies. These injections have a major role in enhancing the function of the joints and in postponing expensive surgeries, which is the reason for their steady market growth all over the world.

Key Company Development

Ono Pharmaceutical and Seikagaku Corporation have succeeded in reaching a new summit in May 2021 by releasing in Japan JOYCLU 30mg Intra-articular Injection (generic: diclofenac etalhyaluronate sodium), which is a new product. By using their own technology for the binding of hyaluronic acid and diclofenol, Seikagaku has produced a unique drug that not only provides better lubrication but also fights inflammation. Consequently, JOYCLU improves the performance of the joint and resolves the problem of treatment of osteoarthritis, which is an advanced disease in Japan due to the country's aging society issue. In the wake of this event, Seikagaku has decided to introduce the new product line, starting with HyLink, in August 2021. It was conceived as the most recent single-injection viscosupplement for knee osteoarthritis with the aim of simplifying treatment by cutting down the number of injections while delivering sustained relief. In this way, the company affirms not only the needs of the patients but also its commitment to the effectiveness of clinical practice and innovation in musculoskeletal care.

Key Players

Major players in the global collagen and hyaluronic acid intra-articular injection market are Seikagaku Corporation, Bioventus, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Sanofi, Fidia Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Ferring B.V., Dr. Reddy's Laboratories Ltd., Semical Biosurgery, Avanos Medical, Inc., and Maxigen Biotech Inc. (MBI).

Report Attribute Details

Market Size 2024 USD 3,046.46 Million

Market Size 2035 USD 6,324.80 Million

CAGR (2025-2035) 6.15%

Base Year 2024

Market Forecast Period 2025-2035

Historical Data 2019-2024

Market Segmentation Insights

By Product Type: Hyaluronic acid Injection - 6.34%, Collagen Injection - 5.45%.

By Application: Knee Osteoarthritis - 6.52%, Joint Pains - 5.74%.

By Distribution Channel: Hospital Pharmacies - 6.37%, Retail Pharmacies - 5.36%.

Regional Analysis

North America captures most of the global earnings mainly due to the high level of patient education and the early introduction of intra-articular drugs. The U.S. dominates North America's collagen and hyaluronic acid intra-articular injections market at USD 1,211.26 million, with Canada ranking second at USD 170.35 million, highlighting the region's strong demand. Supported by substantial insurance coverage and consistent clinical improvement results, the U.S. market has great accessibility to these treatments.

In Europe, the market expansion continues to be supported by the longer life expectancy of the population and their demand for sophisticated therapies. Germany leads Europe's market at USD 130.61 million, with the UK (USD 94.89 million) and France (USD 83.34 million) following as other key contributors. Germany and France are the two countries that account for the largest part of the market due to the extensive research that has been carried out and the well-established medical networks.

The Asia-Pacific region is full of potential, and thus, the demand is booming in the heavily populated countries. China holds the largest share in Asia-Pacific with USD 127.42 million, whereas India follows with USD 83.96 million, together shaping regional growth.Japan's high-speed technological ecosystem is very supportive of innovation, and China's vast patient pool drives volume growth.

Latin America's market outlook is positive but uneven, with Brazil spearheading adoption due to private healthcare investments. Market expansion is slower in smaller economies due to limited awareness and constrained spending capacity.

The Middle East & Africa market is gradually strengthening with rising demand for orthopedic care. Gulf countries, supported by government-funded health programs, are early adopters of advanced injections. African nations face structural barriers, with access concentrated in urban areas.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
• 1.2 MARKET ATTRACTIVENESS ANALYSIS
• 1.3 GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY PRODUCT TYPE
• 1.4 GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY APPLICATION
• 1.5 GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
• 1.6 GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY REGION

2. MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3. RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4. MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF OSTEOARTHRITIS AND JOINT DISORDERS
  • 4.2.2 GROWING AGING POPULATION
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT
  • 4.3.2 REGULATORY CHALLENGES
• 4.4 OPPORTUNITY
  • 4.4.1 GROWING DEMAND FOR MINIMALLY INVASIVE TREATMENTS

5. MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION AND SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 HYALURONIC ACID INJECTION
• 6.3 COLLAGEN INJECTION
• 6.4 COMBINATION OF HYALURONIC ACID AND COLLAGEN

7. GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 KNEE OSTEOARTHRITIS
• 7.3 JOINT PAIN
• 7.4 VETERINARY APPLICATIONS
• 7.5 POST-OPERATIVE RECOVERY
• 7.6 OTHERS

8. GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACIES
• 8.3 RETAIL PHARMACIES
• 8.4 ONLINE PHARMACIES

9. GLOBAL COLLAGEN AND HYALURONIC ACID INTRA-ARTICULAR INJECTIONS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 RUSSIA
  • 9.3.5 SPAIN
  • 9.3.6 ITALY
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 MALAYSIA
  • 9.4.6 THAILAND
  • 9.4.7 INDONESIA
  • 9.4.8 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
  • 9.5.2 MEXICO
  • 9.5.3 ARGENTINA
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST AND AFRICA
  • 9.6.1 GCC COUNTRIES
  • 9.6.2 SOUTH AFRICA
  • 9.6.3 REST OF MEA

10. COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.1.1 PRODUCT LAUNCH/APPROVAL

11. COMPANY PROFILES

• 11.1 SEIKAGAKU CORPORATION
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 BIOVENTUS, INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 ANIKA THERAPEUTICS, INC
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 ZIMMER BIOMET
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCT OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 SANOFI
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 FERRING B.V.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 DR. REDDY'S LABORATORIES LTD.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCT OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 FIDIA FARMACEUTICI S.P.A
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 SEMICAL BIOSURGERY
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES
• 11.11 AVANOS MEDICAL, INC.
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 KEY STRATEGIES
• 11.12 MAXIGEN BIOTECH INC. (MBI)
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL OVERVIEW
  • 11.12.3 PRODUCTS OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 SWOT ANALYSIS
  • 11.12.6 KEY STRATEGIES

12. DATA CITATIONS